Oxford BioMedica PLC
OTC:OXBDF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
O
|
Oxford BioMedica PLC
OTC:OXBDF
|
UK |
|
M
|
MCE Finance SpA
PAR:MLMCE
|
IT |
|
US Nuclear Corp
OTC:UCLE
|
US |
|
Merit Group PLC
F:HXP0
|
UK |
|
Spark Energy Minerals Inc
F:8PC
|
CA |
|
R
|
Rank Group PLC
XMUN:RNKA
|
UK |
|
Neoen SA
PAR:NEOEN
|
FR |
|
Abitare In SpA
F:1BN
|
IT |
|
K
|
Kaken Pharmaceutical Co Ltd
TSE:4521
|
JP |
|
Thinkpath Inc
OTC:THPHF
|
CA |
|
Trinex Minerals Ltd
ASX:TX3
|
AU |
|
Moringa Acquisition Corp
NASDAQ:MACA
|
US |
|
S
|
Soc Nat Proprietes d'Immeubles SCA
PAR:MLPRI
|
FR |
Wall St Price Targets
OXBDF Price Targets Summary
Oxford BioMedica PLC
According to Wall Street analysts, the average 1-year price target for OXBDF is 12.59 USD with a low forecast of 11.28 USD and a high forecast of 16.7 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is OXBDF's stock price target?
Price Target
12.59
USD
According to Wall Street analysts, the average 1-year price target for OXBDF is 12.59 USD with a low forecast of 11.28 USD and a high forecast of 16.7 USD.
What is the Revenue forecast for Oxford BioMedica PLC?
Projected CAGR
18%
Over the last 14 years, the compound annual growth rate for Revenue has been 25%. The projected CAGR for the next 8 years is 18%.
What is the Gross Profit forecast for Oxford BioMedica PLC?
Projected CAGR
23%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 17%. The projected CAGR for the next 8 years is 23%.
